Amylyx is proud to announce that Health Canada has approved ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for the treatment of amyotrophic lateral sclerosis (ALS). ALBRIOZA (also known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death in people living with ALS, either as a stand-alone therapy or when added to existing treatments.
More moments
like this
Everything we do at Amylyx is centered around those living with neurodegenerative diseases. In a relentless pursuit to preserve every moment, we’re working to discover and develop new treatments with the potential to give people more quality time with the ones they love.
And this
And this
Because these are the moments that truly matter.
Health Canada Approves ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine) for the Treatment of ALS
EMA Validation of MAA for AMX0035 for the Treatment of ALS
Amylyx is proud to announce that the European Medicines Agency (EMA) has validated our Marketing Authorisation Application (MAA) for AMX0035 for the treatment of ALS and is now reviewing our MAA.
In pursuit of more
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn about our unique culture, approach to clinical trials for AMX0035, and more.
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn about our unique culture, approach to clinical trials for AMX0035, and more.
Driven by People
“When you're diagnosed with ALS [amyotrophic lateral sclerosis], you're no longer on the human clock, you're on the ALS clock. Every passing day is a lifetime to an ALS patient, and ALS patients don't have time to wait.”
Cali, ALS caregiver
“I feel like Amylyx is a very different company than most that I work with and truly seems like a company that cares, with a big heart, but further than that is they have a fierceness in them and they’re not going to back down from so many of the obstacles that people living with ALS have been facing.”
Sandy, Person living with ALS
“I believe in Amylyx, I think they are truly patient-centric. They don't talk the talk, they walk the walk.”
Gwen, Person living with ALS
“You require help, that in the years prior, you never needed — where people have to change their lifestyle, to make your lifestyle. So, it doesn't just affect you, it affects the ones around you.”
Greg, Person living with ALS
In the Moment
Latest News
Next
An error has occurred. Please refresh the page and retry.
Keep in touch
We’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.